All In Biotech

Drug Trial Radar · NCT05602675

A Drug Interaction Study of LY3871801 in Healthy Participants

Evaluation of the Effect of LY3871801 on the Pharmacokinetics of CYP450 Substrates and an OAT1/3 Substrate in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Apr 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

39

Actual

Start

Nov 2, 2022

Primary completion

Mar 29, 2023

Study completion Mar 29, 2023

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Nov 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of this study is to determine the effect of LY3871801 when administered orally on the levels of methotrexate (part 1), drug cocktail (warfarin, dextromethorphan, and midazolam) and repaglinide (part 2) in the blood stream when administered orally in healthy participants. The information about any adverse effects experienced will be collected and the tolerability of LY3871801 will also be evaluated. The study may last up to approximately 25 days for each participant.

Conditions

  • Healthy

Interventions

  • LY3871801Drug

    Administered orally.

  • MethotrexateDrug

    Administered orally.

  • WarfarinDrug

    Administered orally.

  • DextromethorphanDrug

    Administered orally.

  • MidazolamDrug

    Administered orally.

  • RepaglinideDrug

    Administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Pharmacokinetics (PK): Maximum Concentration (Cmax) of MethotrexateTime frame: Predose up to 48 hours postdose
  2. Part 1: PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of MethotrexateTime frame: Predose up to 48 hours postdose
  3. Part 2: PK: Cmax of MidazolamTime frame: Predose up to 24 hours postdose
  4. Part 2: PK: AUC[0-∞] of MidazolamTime frame: Predose up to 24 hours postdose
  5. Part 2: PK: Cmax of S-warfarinTime frame: Predose up to 96 hours postdose
  6. Part 2: PK: AUC[0-∞] of S-warfarinTime frame: Predose up to 96 hours postdose
  7. Part 2: PK: Cmax of DextromethorphanTime frame: Predose up to 72 hours postdose
  8. Part 2: PK: AUC[0-∞] of DextromethorphanTime frame: Predose up to 72 hours postdose
  9. Part 2: PK: Cmax of RepaglinideTime frame: Predose up to 24 hours postdose
  10. Part 2: PK: AUC[0-∞] of RepaglinideTime frame: Predose up to 24 hours postdose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Covance Dallas

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.